project id: TCGA-UCEC; case submitter id: TCGA-AX-A3G9; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.2; rna integrity number: 8.2; age at index: 63; days to birth: -23361; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 23361; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 558.0; figo stage: Stage IIIC; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 560; initial weight: 110.0; oct embedded: false; preservation method: Unknown; sample id: 739cf2f3-e9eb-4f4a-8310-2d7413e323e4; sample submitter id: TCGA-AX-A3G9-01A; portion id: 96b698a8-9ba6-4437-b6be-fa6d38a73466; portion submitter id: TCGA-AX-A3G9-01A-11; slide id: cfdd8b54-73d9-4e70-a5fd-852c0fe3ac11; slide submitter id: TCGA-AX-A3G9-01A-01-TS1; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 5.0; percent tumor cells: 83.0; percent tumor nuclei: 90.0; section location: TOP;